OpenAlex
PricingAboutJobs
Log inGet started
Work

Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas.

HTML

Year: 2013
Type: conference-abstract
Source: Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.targ-13-a276
Authors: Jeffrey R. Infante, Geoffrey I. Shapiro, Petronella O. Witteveen, John F. Gerecitano, Vincent Ribrag, Rashmi Chugh, Abhijit Chakraborty, Alessandro Matano, Xumei Zhao, Sudha Parasuraman, Philippe A. Cassier
Institutions: Sarah Cannon, Tennessee Oncology, Dana-Farber Cancer Institute, University Medical Center Utrecht, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, University of Michigan, Novartis (Switzerland), Centre Léon Bérard
Language: English

Topic: Advanced Breast Cancer Therapies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: ribociclib, CDK4/6 inhibitors, CDK4, CDK6, cyclin D1, cyclin D3, retinoblastoma protein, advanced solid tumors, lymphoma, maximum tolerated dose, recommended dose, dose-limiting toxicity, pharmacokinetics, QTc prolongation, hematologic toxicity, gastrointestinal toxicity
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2077611283
Cites:
Cited by: 19
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security